SteadySharesSteadyShares
Try now

Johnson & Johnson (JNJ)

Healthcare · NYSE · US

$249.97+6.29% today

Fundamentals

Market cap$618.61B
P/E ratio29.8
Dividend yield2.07%
Revenue growth (YoY)+9.9%
Profit margin21.8%
Return on equity26.4%
52-week range$162.30 to $269.43
Next earnings2026-07-15

Valuation and ratings

DCF fair value$168.00
Upside to fair value-32.8%
Analyst target (mean)$258.59
Analyst range$190.00 to $298.00
Analysts covering22
Consensus viewbuy
Moat score76/100
Overall rating70/100, Strong Buy

Johnson & Johnson trades at $249.97, which is 33% above the $168.00 our discounted cash flow model puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.

Our moat model scores it 76 out of 100, which is a wide moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.

It changes hands at 29.8 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry: Drug Manufacturers - GeneralEmployees: 138,200HQ: United States

JNJ passes 6 of our 30 screens today

Each screen prints the exact criteria it used, and the circumstances in which it is wrong.

Wide moat compounders
Businesses with a structural reason competitors cannot take their profits away. The rarest and most valuable thing in investing.
Growing dividend payers
A modest yield attached to a growing business beats a large yield attached to a shrinking one, every time, over any horizon that matters.
Low volatility defensives
Companies that move less than the market and pay you to wait. The holdings that let you sleep, and let you hold everything else.
Highest conviction
The best overall scores in our universe, restricted to companies where we actually hold enough data to have an opinion worth reading.
Healthcare and pharma
Drug companies are engines that convert one expiring monopoly into the next. The patent cliff is the whole investment case.
Dividend aristocrats
Companies with long, unbroken records of raising their dividend. The record is the point: it is evidence, not a promise.

Smart money ownership

28 of the funds we track reported a position in their latest SEC 13F filing. Largest first:

A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.

Common questions

Is Johnson & Johnson (JNJ) undervalued?

Against our discounted cash flow estimate of $168.00, JNJ at $249.97 is 33% above fair value. That is one model's answer, not a recommendation, and most of a DCF's output sits in a terminal value nobody can forecast.

Which funds own JNJ?

28 of the institutions we track reported a position in JNJ in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.

What is JNJ's P/E ratio?

JNJ trades at 29.8 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.

The full research page for JNJ, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.

Open JNJ in the appFree guides and screens

Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.